Literature DB >> 16888019

NK cells use NKG2D to recognize a mouse renal cancer (Renca), yet require intercellular adhesion molecule-1 expression on the tumor cells for optimal perforin-dependent effector function.

Karen Abdool1, Erika Cretney, Alan D Brooks, Janice M Kelly, Jeremy Swann, Anil Shanker, Earl W Bere, Wayne M Yokoyama, John R Ortaldo, Mark J Smyth, Thomas J Sayers.   

Abstract

The NKG2D receptor on NK cells can recognize a variety of ligands on the tumor cell surface. Using a mouse renal cancer (Renca), we show that NKG2D recognition by NK cells was crucial for their ability to limit tumor metastases in vivo in both liver and lungs using perforin-dependent effector mechanisms. However, for the R331 cell line established from Renca, NKG2D recognition and perforin-dependent lysis played no role in controlling liver metastases. R331 cells were also more resistant to perforin-dependent lysis by NK cells in vitro. We therefore used these phenotypic differences between Renca and R331 to further investigate the crucial receptor:ligand interactions required for triggering lytic effector functions of NK cells. Reconstitution of R331 cells with ICAM-1, but not Rae-1gamma, restored NKG2D-mediated, perforin-dependent lysis. Interestingly, R331 cells were efficiently lysed by NK cells using death ligand-mediated apoptosis. This death ligand-mediated killing did not depend on NKG2D recognition of its ligands on tumor cells. This result suggests that the intracellular signaling in NK cells required for perforin and death ligand-mediated lysis of tumor target cell are quite distinct, and activation of both of these antitumor lytic effector functions of NK cells could improve therapeutic benefits for certain tumors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16888019     DOI: 10.4049/jimmunol.177.4.2575

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

1.  Reduction of GVHD and enhanced antitumor effects after adoptive infusion of alloreactive Ly49-mismatched NK cells from MHC-matched donors.

Authors:  Andreas Lundqvist; J Philip McCoy; Leigh Samsel; Richard Childs
Journal:  Blood       Date:  2006-12-19       Impact factor: 22.113

2.  Combination therapy using IL-2 and anti-CD25 results in augmented natural killer cell-mediated antitumor responses.

Authors:  William H D Hallett; Erik Ames; Maite Álvarez; Isabel Barao; Patricia A Taylor; Bruce R Blazar; William J Murphy
Journal:  Biol Blood Marrow Transplant       Date:  2008-10       Impact factor: 5.742

Review 3.  T Cells and Regulated Cell Death: Kill or Be Killed.

Authors:  Johan Spetz; Adam G Presser; Kristopher A Sarosiek
Journal:  Int Rev Cell Mol Biol       Date:  2018-08-29       Impact factor: 6.813

4.  Delineation of antigen-specific and antigen-nonspecific CD8(+) memory T-cell responses after cytokine-based cancer immunotherapy.

Authors:  Julia K Tietze; Danice E C Wilkins; Gail D Sckisel; Myriam N Bouchlaka; Kory L Alderson; Jonathan M Weiss; Erik Ames; Kevin W Bruhn; Noah Craft; Robert H Wiltrout; Dan L Longo; Lewis L Lanier; Bruce R Blazar; Doug Redelman; William J Murphy
Journal:  Blood       Date:  2012-01-17       Impact factor: 22.113

5.  Enhanced natural killer activity and production of pro-inflammatory cytokines in mice selected for high acute inflammatory response (AIRmax).

Authors:  Lindsey Castoldi; Marjorie Assis Golim; Orlando Garcia Ribeiro Filho; Graziela Gorete Romagnoli; Olga Célia Martinez Ibañez; Ramon Kaneno
Journal:  Immunology       Date:  2006-12-08       Impact factor: 7.397

6.  Dissection of spontaneous cytotoxicity by human intestinal intraepithelial lymphocytes: MIC on colon cancer triggers NKG2D-mediated lysis through Fas ligand.

Authors:  Ellen C Ebert; Veronika Groh
Journal:  Immunology       Date:  2008-02-13       Impact factor: 7.397

7.  Diet-induced obesity alters dendritic cell function in the presence and absence of tumor growth.

Authors:  Britnie R James; Ann Tomanek-Chalkley; Eric J Askeland; Tamara Kucaba; Thomas S Griffith; Lyse A Norian
Journal:  J Immunol       Date:  2012-06-27       Impact factor: 5.422

8.  Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells.

Authors:  Andreas Lundqvist; Hisayuki Yokoyama; Aleah Smith; Maria Berg; Richard Childs
Journal:  Blood       Date:  2009-02-06       Impact factor: 22.113

9.  Combination immune therapies to enhance anti-tumor responses by NK cells.

Authors:  Ashley Mentlik James; Adam D Cohen; Kerry S Campbell
Journal:  Front Immunol       Date:  2013-12-23       Impact factor: 7.561

10.  The Antidiabetic Agent Acarbose Improves Anti-PD-1 and Rapamycin Efficacy in Preclinical Renal Cancer.

Authors:  Rachael M Orlandella; William J Turbitt; Justin T Gibson; Shannon K Boi; Peng Li; Daniel L Smith; Lyse A Norian
Journal:  Cancers (Basel)       Date:  2020-10-06       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.